HomeComparePROG vs PLD

PROG vs PLD: Dividend Comparison 2026

PROG yields 226.12% · PLD yields 3.10%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 PROG wins by $241.41M in total portfolio value
10 years
PROG
PROG
● Live price
226.12%
Share price
$0.88
Annual div
$2.00
5Y div CAGR
0%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$247.32M
Annual income
$132,258,559.01
Full PROG calculator →
PLD
PLD
● Live price
3.10%
Share price
$132.18
Annual div
$4.10
5Y div CAGR
74.4%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$5.91M
Annual income
$4,750,725.19
Full PLD calculator →

Portfolio growth — PROG vs PLD

📍 PROG pulled ahead of the other in Year 1

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodPROGPLD
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, PROG + PLD cover 0 of 12 monthsgood coverage

Jan
Feb
Mar
Apr
May
Jun
Jul
Aug
Sep
Oct
Nov
Dec
PROG pays
PLD pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

PROG
Annual income on $10K today (after 15% tax)
$19,219.90/yr
After 10yr DRIP, annual income (after tax)
$112,419,775.16/yr
PLD
Annual income on $10K today (after 15% tax)
$263.66/yr
After 10yr DRIP, annual income (after tax)
$4,038,116.41/yr
At 15% tax rate, PROG beats the other by $108,381,658.75/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of PROG + PLD for your $10,000?

PROG: 50%PLD: 50%
100% PLD50/50100% PROG
Portfolio after 10yr
$126.61M
Annual income
$68,504,642.10/yr
Blended yield
54.11%
📊

Analyst Conviction Gap

Where Wall Street is most bullish on PLD right now

PROG
Analyst Ratings
2
Buy
2
Hold
1
Sell
Consensus: Buy
Price Target
$4.00
+352.2% upside vs current
Range: $4.00 — $4.00
Altman Z
-19.8
Piotroski
4/9
PLD
Analyst Ratings
25
Buy
16
Hold
1
Sell
Consensus: Buy
Price Target
$136.00
+2.9% upside vs current
Range: $119.00 — $155.00
Altman Z
1.9
Piotroski
5/9
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

PROG buys
0
PLD buys
0
No recent congressional trades found for PROG or PLD in the last 90 days.
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricPROGPLD
Forward yield226.12%3.10%
Annual dividend / share$2.00$4.10
Payout ratio50%50%
1-year div growth0%0%
5-year div CAGR0%74.4%
Portfolio after 10y$247.32M$5.91M
Annual income after 10y$132,258,559.01$4,750,725.19
Total dividends collected$234.58M$5.78M
Payment frequencyquarterlyquarterly
SectorStockREIT
Analyst consensusBuyBuy
Analyst price target$4.00$136.00

Year-by-year: PROG vs PLD ($10,000, DRIP)

YearPROG PortfolioPROG Income/yrPLD PortfolioPLD Income/yrGap
1← crossover$33,312$22,611.64$11,241$540.96+$22.1KPROG
2$106,039$70,395.43$13,019$991.13+$93.0KPROG
3$322,887$209,425.60$15,801$1,870.97+$307.1KPROG
4$941,469$595,979.98$20,609$3,701.21+$920.9KPROG
5$2,631,436$1,624,064.27$29,919$7,867.97+$2.60MPROG
6$7,057,984$4,242,346.63$50,631$18,617.74+$7.01MPROG
7$18,186,373$10,634,330.10$105,528$51,352.20+$18.08MPROG
8$45,068,370$25,608,951.52$287,364$174,449.42+$44.78MPROG
9$107,533,957$59,310,801.02$1,081,760$774,280.77+$106.45MPROG
10$247,319,893$132,258,559.01$5,908,209$4,750,725.19+$241.41MPROG

PROG vs PLD: Complete Analysis 2026

PROGStock

Progenity, Inc., a biotechnology company, provides develops and commercializes molecular testing products in the United States. The company develops targeted oral delivery of biotherapeutics, including PGN-600, an orally delivered liquid formulation of tofacitinib for the treatment of ulcerative colitis; and PGN-001, an orally delivered variant of adalimumab for the treatment of ulcerative colitis. It also develops systemic oral delivery of biotherapeutics, which include PGN-OB, a combination product of a variant of adalimumab and the Oral Biotherapeutics Delivery System (OBDM) for the treatment of inflammatory conditions; and PGN-OB2, a combination product of a GLP-1 receptor agonist and the OBDS for the treatment of Type 2 diabetes. In addition, the company develops Recoverable Sampling System, an ingestible smart capsule designed to autonomously identify locations in the GI tract, collect, and preserve a sample for analysis; and PIL Dx, an ingestible smart capsule designed to sample, measure, and transmit results. It has partnership agreement with Ionis Pharmaceuticals to evaluate the OBDS for delivery of antisense oligonucleotides. The company was formerly known as Ascendant MDX, Inc. and changed its name to Progenity, Inc. in November 2013. The company was founded in 2010 and is headquartered in San Diego, California.

Full PROG Calculator →

PLDREIT

Prologis, Inc. is the global leader in logistics real estate with a focus on high-barrier, high-growth markets. As of December 31, 2020, the company owned or had investments in, on a wholly owned basis or through co-investment ventures, properties and development projects expected to total approximately 984 million square feet (91 million square meters) in 19 countries. Prologis leases modern logistics facilities to a diverse base of approximately 5,500 customers principally across two major categories: business-to-business and retail/online fulfillment.

Full PLD Calculator →
📬

Get this PROG vs PLD comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

PROG vs SCHDPROG vs JEPIPROG vs OPROG vs KOPROG vs MAIN

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.